Abstract:<p>Immune checkpoints blockades have shown promising clinical effects in various malignancies, but the overall response rate is low. Here, the immune features are comprehensively characterized in >10 000 cancer patients from The Cancer Genome Atlas and significantly positive correlations are observed between targets of Sunitinib and inhibitory immune checkpoints and suppressive immune cells. It is further confirmed that Sunitinib treatment increases the antitumor immunity in a phase III trial. Mechanistically, it is discovered that Sunitinib regulates the stability of tumor PD‐L1 via p62, that p62 can bind to PD‐L1 and specifically promote its translocation into autophagic lysosome for degradation. Preclinically, Sunitinib shows a synergistic antitumor effect with cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) monoclonal antibody (mAb) in melanoma and nonsmall cell lung cancer (NSCLC) immune competent mice by promoting the tumor‐infiltrating lymphocytes activity. Clinically, a higher PD‐L1 level but a lower p62 level in the tumor region of responders as compared to those of nonresponders among anti‐PD‐1‐treated NSCLC patients is observed. Taken together, by utilizing rigorous computational analysis, functional characterization in vitro and in vivo, and neoadjuvent clinical trial, a novel molecular mechanism is revealed regarding the regulation of PD‐L1 via p62, thus providing a novel therapeutic strategy by the combination treatment of CTLA‐4 with Sunitinib.</p>

What problem does this paper attempt to address?

The key problem that this paper attempts to solve is to improve the efficacy of tumor immunotherapy, especially by regulating the PD - L1 level in tumor cells to enhance anti - tumor immunity. Specifically, the researchers explored the role of sunitinib in tumor immune surveillance and whether it is involved in regulating the PD - L1 level. The study found that sunitinib can down - regulate the protein stability of PD - L1 in tumor cells through the p62 - mediated selective autophagy pathway, thereby increasing the anti - tumor cytotoxic T - lymphocyte (CTL) activity. In addition, the study also revealed the synergistic anti - tumor effect of the combined use of sunitinib and CTLA - 4 monoclonal antibody in immunocompetent mouse models of melanoma and non - small - cell lung cancer, providing a new strategy for improving the therapeutic effect of immune checkpoint inhibitors. ### Main findings: 1. **The correlation between sunitinib and immunosuppressive cells and inhibitory immune checkpoints**: - The study found that the targets of sunitinib are significantly positively correlated with multiple immunosuppressive cell types (such as tumor - associated macrophages, myeloid - derived suppressor cells, and regulatory T cells) and inhibitory immune checkpoints in multiple cancer types. - In clinical trials, the combination of sunitinib and docetaxel in the treatment of patients with metastatic breast cancer significantly enhanced the expression of IFN - γ - related genes, the level of CD8A transcripts, and cytolytic activity, indicating that sunitinib treatment is related to the increase in T - cell infiltration and activity. 2. **Sunitinib enhances CTL activity by reducing tumor PD - L1 levels**: - In vitro and in vivo experiments showed that after sunitinib treatment, the tumor PD - L1 protein level decreased significantly, while the mRNA level was not affected, indicating that its effect is mainly at the post - translational level. - Sunitinib treatment increased the number of tumor - infiltrating activated CD8+T cells, and the PD - L1 level was strongly negatively correlated with the CTL population size. 3. **Sunitinib regulates PD - L1 through p62 - mediated selective autophagy**: - The study found that after sunitinib treatment, the number of intracellular autophagosomes and lysosomes increased, and the expression levels of p62 and LC3II also increased significantly. - Further experiments confirmed that p62 interacts with PD - L1 and transports it to autophagosomes and lysosomes for degradation, thereby reducing the protein level of PD - L1. 4. **The synergistic effect of the combined use of sunitinib and CTLA - 4 monoclonal antibody**: - In immunocompetent mouse models of melanoma and non - small - cell lung cancer, the combined use of sunitinib and CTLA - 4 monoclonal antibody significantly inhibited tumor growth and prolonged survival. - The combined treatment significantly reduced the PD - L1 level in the tumor area, increased the number of CD8+CTLs and enhanced their activity. 5. **The correlation between p62 expression level and the therapeutic effect of PD - L1 monoclonal antibody**: - In non - small - cell lung cancer patients receiving PD - 1 monoclonal antibody treatment, patients with low p62 expression showed better progression - free survival (PFS) and overall survival (OS). - The p62 level was higher and the PD - L1 level was lower in the tumor area of non - responding patients, further supporting the key role of p62 in PD - L1 regulation. ### Conclusion: This study reveals a new mechanism by which sunitinib down - regulates the tumor PD - L1 level through the p62 - mediated selective autophagy pathway, providing a new strategy for improving the therapeutic effect of immune checkpoint inhibitors. These findings not only enhance the understanding of the tumor immune surveillance mechanism but also provide a theoretical basis for the development of more effective combined treatment regimens.

The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

The Progress of PD-1 Inhibitors in Small-Cell Lung Cancer

Sunitinib Impairs the Proliferation and Function of Human Peripheral T Cell and Prevents T-cell-mediated Immune Response in Mice.

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC

Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo.

Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade

A multifunctional PEGylated liposomal-encapsulated sunitinib enhancing autophagy, immunomodulation, and safety in renal cell carcinoma

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity Via Immunogenic Cell Death and Macrophage Reprogramming

Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‐1 antibody suppresses the progression of non‐small cell lung cancer tumors by enhancing immunocompetence

Key sunitinib-related biomarkers for renal cell carcinoma

Tumor-immune Microenvironment and NRF2 Associate with Clinical Efficacy of PD-1 Blockade Combined with Chemotherapy in Lung Squamous Cell Carcinoma.

Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma

The Evaluation of Efficacy and Safety of Sunitinib on EGFR‐TKI Pretreated Advanced Non‐small Cell Lung Cancer Patients in China

Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors

Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer

Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer